中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 36 Issue 10
Oct.  2020
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2020  >  36(10): 2184-2187

Clinical significance of heterogeneity in multifocal hepatocellular carcinoma: A multi-omics study

DOI: 10.3969/j.issn.1001-5256.2020.10.005

  • Department of Liver Surgery,The First Affiliated Hospital of Sun Yat-sen University

  • Department of Oncology,The First Affiliated Hospital of Sun Yat-sen University

  • Department of Radiotherapy,The First Affiliated Hospital of Sun Yat-sen University

Research funding:

 

  • Received Date: 2020-08-24
  • Published Date: 2020-10-20
    Abstract
  • More than half of patients with hepatocellular carcinoma( HCC) have multiple lesions in the liver at the time when they attend the hospital,and there are limited treatment methods with poor efficacy for multifocal HCC in clinical practice. The high degree of tumor heterogeneity in multifocal HCC is the leading cause of treatment failure. More and more studies use multi-omics sequencing to explore the heterogeneity between different lesions at the genetic and transcriptional levels,including tumor clonal evolution,gene mutations,copy number variations,structural variations,RNA expression,and tumor immune microenvironment. Drug target distribution shaped by clonal evolution and the characteristics of immune microenvironment can accurately predict the response to targeted drugs and immunotherapy in patients with multifocal HCC. Therefore,a comprehensive and accurate assessment of the heterogeneity of multifocal HCC based on a multi-omics study is of vital importance in the implementation of precise treatment.

     

    • FullText(HTML)
    • References(41)
  • [1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
    [2] CHEN W,ZHENG R,BAADE PD,et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
    [3] KUDO M,IZUMI N,ICHIDA T,et al. Report of the 19th follow-up survey of primary liver cancer in Japan[J]. Hepatol Res,2016,46(5):372-390.
    [4] DONG LQ,PENG LH,MA LJ,et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma[J]. J Hepatol,2020,72(5):896-908.
    [5] XIE DY,FAN HK,REN ZG,et al. Identifying clonal origin of multifocal hepatocellular carcinoma and its clinical implications[J]. Clin Transl Gastroenterol,2019,10(2):e00006.
    [6] RAMACCIATO G,MERCANTINI P,PETRUCCIANI N,et al.Does surgical resection have a role in the treatment of large or multinodular hepatocellular carcinoma?[J]. Am Surg,2010,76(11):1189-1197.
    [7] BRUIX J,REIG M,SHERMAN M. Evidence-based diagnosis,staging,and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology,2016,150(4):835-853.
    [8] BRUIX J,TAKAYAMA T,MAZZAFERRO V,et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM):A phase 3,randomised,double-blind,placebo-controlled trial[J]. Lancet Oncol,2015,16(13):1344-1354.
    [9] WHITE R,NAIR RL,BRADLEY RH. Theorizing the benefits and costs of adaptive cultures for development[J]. Am Psychol,2018,73(6):727-739.
    [10] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.
    [11] SPINZI G,PAGGI S. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(23):2497-2498;author reply 2498-2499.
    [12] CROCENZI TS,EL-KHOUEIRY AB,YAU TC,et al. Nivolumab(nivo)in sorafenib(sor)-naive and-experienced pts with advanced hepatocellular carcinoma(HCC):CheckMate040 study[J]. 2017,35(15 suppl):4013.
    [13] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate040):an open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
    [14] ZHU AX,FINN RS,EDELINE J,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):A non-randomised,open-label phase 2 trial[J]. Lancet Oncol,2018,19(7):940-952.
    [15] KELLEY RK. Adjuvant sorafenib for liver cancer:Wrong stage,wrong dose[J]. Lancet Oncol,2015,16(13):1279-1281.
    [16] HUANG A,ZHAO X,YANG XR,et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma[J]. J Hepatol,2017,67(2):293-301.
    [17] LIN DC,MAYAKONDA A,DINH HQ,et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma[J]. Cancer Res,2017,77(9):2255-2265.
    [18] TORRECILLA S,SIA D,HARRINGTON AN,et al. Trunk mutational events present minimal intra-and inter-tumoral heterogeneity in hepatocellular carcinoma[J]. J Hepatol,2017,67(6):1222-1231.
    [19] FEO F,PASCALE RM. Multifocal hepatocellular carcinoma:Intrahepatic metastasis or multicentric carcinogenesis?[J].Ann Transl Med,2015,3(1):4.
    [20] GAO Q,WANG ZC,DUAN M,et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents[J]. Gastroenterology,2017,152(1):232-242. e4.
    [21] FURUTA M,UENO M,FUJIMOTO A,et al. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors[J]. J Hepatol,2017,66(2):363-373.
    [22] ZHAI W,LIM TK,ZHANG T,et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma[J]. Nat Commun,2017,8:4565.
    [23] XU LX,HE MH,DAI ZH,et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma[J]. Ann Oncol,2019,30(6):990-997.
    [24] HUANG M,HE M,GUO Y,et al. The influence of immune heterogeneity on the effectiveness of immune checkpoint inhibitors in multifocal hepatocellular carcinomas[J]. Clin Cancer Res,2020,26(18):4947-4957.
    [25] SIA D,JIAO Y,MARTINEZ-QUETGLAS I,et al. Identification of an immune-specific class of hepatocellular carcinoma,based on molecular features[J]. Gastroenterology,2017,153(3):812-826.
    [26] DUAN M,HAO J,CUI S,et al. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing[J]. Cell Res,2018,28(3):359-373.
    [27] BAFFY G. Decoding multifocal hepatocellular carcinoma:An opportune pursuit[J]. Hepatobiliary Surg Nutr,2015,4(3):206-210.
    [28] MORIMOTO O,NAGANO H,SAKON M,et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas[J]. J Hepatol,2003,39(2):215-221.
    [29] YAMAMOTO T,KAJINO K,KUDO M,et al. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA[J]. Hepatology, 1999, 29(5):1446-1452.
    [30] KAWAI S,IMAZEKI F,YOKOSUKA O,et al. Clonality in hepatocellular carcinoma:Analysis of methylation pattern of polymorphic X-chromosome-linked phosphoglycerate kinase gene in females[J]. Hepatology,1995,22(1):112-117.
    [31] MIAO R,LUO H,ZHOU H,et al. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis[J]. J Hepatol,2014,61(4):840-849.
    [32] ZHANG Q,LOU Y,YANG J,et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas[J]. Gut,2019,68(11):2019-2031.
    [33] XUE R,LI R,GUO H,et al. Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma[J]. Gastroenterology,2016,150(4):998-1008.
    [34] CHEN XP,LONG X,JIA WL,et al. Viral integration drives multifocal HCC during the occult HBV infection[J]. J Exp Clin Cancer Res,2019,38(1):261.
    [35] AMIROUCHENE-ANGELOZZI N,SWANTON C,BARDELLI A. Tumor evolution as a therapeutic target[J]. Cancer Discov,2017.[Online ahead of print]
    [36] FALTAS BM,PRANDI D,TAGAWA ST,et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma[J]. Nat Genet,2016,48(12):1490-1499.
    [37] WANG J,CAZZATO E,LADEWIG E,et al. Clonal evolution of glioblastoma under therapy[J]. Nat Genet,2016,48(7):768-776.
    [38] LEE JK,WANG J,SA JK,et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma[J]. Nat Genet,2017,49(4):594-599.
    [39] SCHULZE K,NAULT JC,VILLANUEVA A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing[J]. J Hepatol,2016,65(5):1031-1042.
    [40] Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma[J]. Cell,2017,169(7):1327-1341. e23.
    [41] DING X,HE M,CHAN A,et al. Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas[J]. Gastroenterology,2020.[Online ahead of print]
    • Relative Articles

  • Relative Articles

    [1]Qingxia LIU, Chenggang ZHANG, Haolin TANG, Wenjing QU, Huifan JI, Xiaolin GUO. A case of primary biliary cholangitis with connective tissue disease and immune thrombocytopenia[J]. Journal of Clinical Hepatology, 2023, 39(6): 1404-1407. doi: 10.3969/j.issn.1001-5256.2023.06.022
    [2]Haifeng LIU, Simin ZHOU, Jiwen LI, Jiangpeng LIU, Bangmao WANG, Lu ZHOU. Effect of depression on response to ursodeoxycholic acid and the occurrence of liver cirrhosis in patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2817-2823. doi: 10.3969/j.issn.1001-5256.2023.12.011
    [3]Mei CHEN, Ning MA, Jingbo JIN, Yu PENG, Sitong FAN, Fang WANG. A case of primary biliary cholangitis with megaloblastic anemia[J]. Journal of Clinical Hepatology, 2022, 38(5): 1114-1115. doi: 10.3969/j.issn.1001-5256.2022.05.026
    [4]Xing LYU, Ting LI, Xiaodong SUN, Jianpeng ZHOU, Dongxia WANG, Guoyue LYU. Research advances in the treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(9): 2130-2135. doi: 10.3969/j.issn.1001-5256.2022.09.035
    [5]Fang QIU, Chan WANG, Mingming ZHANG, Xingjuan SHI, Xiangdong LIU. Genetic studies of primary biliary cholangitis in the post-GWAS era[J]. Journal of Clinical Hepatology, 2022, 38(4): 759-761. doi: 10.3969/j.issn.1001-5256.2022.04.005
    [6]Haitao MA, Yingmei TANG. Research advances in exosomes in primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1896-1900. doi: 10.3969/j.issn.1001-5256.2022.08.035
    [7]Chinese Society of Hepatology. Guidelines on the diagnosis and management of primary biliary cholangitis (2021)[J]. Journal of Clinical Hepatology, 2022, 38(1): 35-41. doi: 10.3760/cma.j.cn112138-20211112-00794
    [8]Xi CHU, Lianjun XING. Role of anion exchanger 2 in the pathogenesis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2021, 37(3): 718-720. doi: 10.3969/j.issn.1001-5256.2021.03.044
    [9]Yafei YANG, Zhihua DENG. Immune mechanism of biliary epithelial cell injury in the small intrahepatic bile ducts in primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2021, 37(6): 1466-1468. doi: 10.3969/j.issn.1001-5256.2021.06.051
    [10]Jia Gui, Shang YuLong, Han Ying. An investigation of quality of life and treatment of patients with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(9): 2021-2024. doi: 10.3969/j.issn.1001-5256.2020.09.022
    [11]Wang XiaoJing, Liu Yao, Wang XianBo. Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(1): 26-30. doi: 10.3969/j.issn.1001-5256.2020.01.004
    [12]Ma WeiYu, Deng ZhiHua. Current status of immunogenetic studies on primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 932-935. doi: 10.3969/j.issn.1001-5256.2020.04.050
    [13]Wei Jing, Wu XiRun. Current status of research on fibrates in treatment of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(2): 442-445. doi: 10.3969/j.issn.1001-5256.2020.02.046
    [14]Tu RongFang, Yang Xue, Tang YingMei. Research advances in primary biliary cholangitis with extrahepatic autoimmune diseases[J]. Journal of Clinical Hepatology, 2020, 36(6): 1398-1401. doi: 10.3969/j.issn.1001-5256.2020.06.046
    [15]Yang Ning, Liu YanSheng, Han Ying. Diagnosis and treatment of primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Journal of Clinical Hepatology, 2020, 36(3): 697-700. doi: 10.3969/j.issn.1001-5256.2020.03.051
    [16]Shu YanYun, Pan XiaoLi, Song YuHu, Ye Jin. Clinical features of autoimmune hepatitis and primary biliary cholangitis: A comparative analysis[J]. Journal of Clinical Hepatology, 2019, 35(2): 354-358. doi: 10.3969/j.issn.1001-5256.2019.02.022
    [17]Wang Jing, Zhang BiQing, Pan YunZhi, Zhu ChuanWu. Role of microRNA in the pathogenesis, diagnosis, and outcome evaluation of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1636-1639. doi: 10.3969/j.issn.1001-5256.2019.07.047
    [18]Yang QianQian, Ren TianQi, Xue ShuWen, Chen QingLing, Feng LiNa, Zhang XiaoXue, Wen XiaoYu, Jin QingLong. Primary biliary cholangitis with myelofibrosis: A case report[J]. Journal of Clinical Hepatology, 2019, 35(9): 2057-2058. doi: 10.3969/j.issn.1001-5256.2019.09.036
    [19]Wang Jing, Zhao LiLi, Shi RuiFang, Liu YongGang, Li Jia. Early treatment of PBC-AIH overlap syndrome with histological remission: A case report[J]. Journal of Clinical Hepatology, 2019, 35(9): 2059-2061. doi: 10.3969/j.issn.1001-5256.2019.09.037
    [20]Li ShuXiang, Duan WeiJia, Zhang Dong, You Hong, Jia JiDong. Research advances in autoimmune hepatitis and primary biliary cholangitis in 2017[J]. Journal of Clinical Hepatology, 2018, 34(7): 1569-1572. doi: 10.3969/j.issn.1001-5256.2018.07.044
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(5)

    1. 王耀磊，王盼攀. 肝门部胆管癌患者术后并发症发生情况及其影响因素的Logistic回归分析. 医学理论与实践. 2024(11): 1822-1825 .
    2. 李明，于群，肖熙，刘影倩，黄裕存. 外科Apgar评分及POSSUM评分对老年严重胸部外伤术后预后的评估价值. 名医. 2023(09): 30-32 .
    3. 朱磊，赵海淳，李珊珊，孟君. 外科Apgar评分对术前新辅助化疗进展期胃癌术后并发症的预测价值. 中国现代普通外科进展. 2022(12): 990-993 .
    4. 章周海，涂从银. 肝门部胆管癌的手术疗效分析. 肝胆外科杂志. 2021(03): 223-225 .
    5. 遆军锋，温陈，张小云，姜丹丹. 肝门部胆管癌术后并发症发生危险因素及术前外科改良 Apgar评分、血清总胆红素水平对并发症的预测价值. 陕西医学杂志. 2021(12): 1513-1516 .

    Other cited types(0)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.4 %FULLTEXT: 4.4 %META: 93.1 %META: 93.1 %PDF: 2.6 %PDF: 2.6 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.7 %其他: 5.7 %其他: 0.4 %其他: 0.4 %Central District: 0.2 %Central District: 0.2 %China: 0.4 %China: 0.4 %India: 0.2 %India: 0.2 %Osaka: 0.4 %Osaka: 0.4 %[]: 0.5 %[]: 0.5 %上海: 5.1 %上海: 5.1 %北京: 6.4 %北京: 6.4 %南宁: 0.2 %南宁: 0.2 %台州: 2.0 %台州: 2.0 %吉林: 0.9 %吉林: 0.9 %哈利法克斯: 0.7 %哈利法克斯: 0.7 %哈尔滨: 0.2 %哈尔滨: 0.2 %宣城: 0.2 %宣城: 0.2 %张家口: 2.0 %张家口: 2.0 %徐州: 0.2 %徐州: 0.2 %昆明: 0.2 %昆明: 0.2 %杭州: 1.6 %杭州: 1.6 %济南: 0.2 %济南: 0.2 %湖州: 1.5 %湖州: 1.5 %潍坊: 0.2 %潍坊: 0.2 %纳什维尔: 0.2 %纳什维尔: 0.2 %纽约: 0.2 %纽约: 0.2 %芒廷维尤: 35.9 %芒廷维尤: 35.9 %莫斯科: 2.4 %莫斯科: 2.4 %葵涌: 0.2 %葵涌: 0.2 %衢州: 0.7 %衢州: 0.7 %西宁: 29.4 %西宁: 29.4 %西安: 0.2 %西安: 0.2 %金华: 0.4 %金华: 0.4 %长春: 0.5 %长春: 0.5 %长治: 0.2 %长治: 0.2 %香港特别行政区: 0.4 %香港特别行政区: 0.4 %黄冈: 0.2 %黄冈: 0.2 %其他其他Central DistrictChinaIndiaOsaka[]上海北京南宁台州吉林哈利法克斯哈尔滨宣城张家口徐州昆明杭州济南湖州潍坊纳什维尔纽约芒廷维尤莫斯科葵涌衢州西宁西安金华长春长治香港特别行政区黄冈

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1531) PDF downloads(175) Cited by(5)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[3692]YesterdayPV[7162]TodayIP[5438]TodayPV[11685]Online[133]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return